

Elena Tragni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2362057/publications.pdf>

Version: 2024-02-01

21
papers

364
citations

933264

10
h-index

794469

19
g-index

21
all docs

21
docs citations

21
times ranked

697
citing authors

#	ARTICLE	IF	CITATIONS
1	Potentially Inappropriate Prescribing among Elderly Outpatients: Evaluation of Temporal Trends 2012-2018 in Piedmont, Italy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3612.	1.2	2
2	Evaluation of Factors Associated With Appropriate Drug Prescription and Effectiveness of Informative and Educational Interventions- The EDU.RE.DRUG Project. <i>Frontiers in Pharmacology</i> , 2022, 13, 832169.	1.6	2
3	The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6724.	1.2	6
4	Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategies. <i>Pharmacological Research</i> , 2020, 155, 104514.	3.1	20
5	A pragmatic controlled trial to improve the appropriate prescription of drugs in adult outpatients: design and rationale of the EDU.RE.DRUG study. <i>Primary Health Care Research and Development</i> , 2020, 21, .	0.5	4
6	Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study. <i>Atherosclerosis</i> , 2020, 301, 1-7.	0.4	11
7	Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies. <i>Atherosclerosis Supplements</i> , 2020, 42, e41-e48.	1.2	8
8	Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. <i>Stroke</i> , 2019, 50, 1758-1765.	1.0	23
9	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. <i>Pharmacological Research</i> , 2019, 143, 143-150.	3.1	25
10	Tools to investigate and avoid drug-hypersensitivity in drug development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 425-433.	2.5	10
11	Use of proton pump inhibitors and risk of ischemic events in the general population. <i>Atherosclerosis</i> , 2018, 277, 123-129.	0.4	21
12	Epidemiology of cardiovascular risk factors in two population-based studies. <i>Atherosclerosis Supplements</i> , 2018, 35, e14-e20.	1.2	6
13	A simple informative intervention in primary care increases statin adherence. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 227-234.	0.8	5
14	Reply to: "Statins probably do not cause cataracts". <i>Atherosclerosis</i> , 2016, 254, 311-312.	0.4	0
15	Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 254, 172-178.	0.4	13
16	Statin use and risk of cataract: A nested case-control study within a healthcare database. <i>Atherosclerosis</i> , 2016, 251, 153-158.	0.4	20
17	Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. <i>European Journal of Internal Medicine</i> , 2014, 25, 745-750.	1.0	37
18	Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study. <i>Diabetes Care</i> , 2014, 37, 2225-2232.	4.3	83

#	ARTICLE	IF	CITATIONS
19	Prevalence of the Prescription of Potentially Interacting Drugs. PLoS ONE, 2013, 8, e78827.	1.1	41
20	Monitoring statin safety in primary care. Pharmacoepidemiology and Drug Safety, 2007, 16, 652-657.	0.9	8
21	Quantitative analysis of $\hat{1}\pm$, $\hat{1}^2$ -thujone, pulegone, safrole, coumarin and $\hat{1}^2$ -asarone in alcoholic beverages by selected-ion monitoring. Journal of Applied Toxicology, 1984, 4, 273-276.	1.4	19